European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe
|
|
- Easter Short
- 7 years ago
- Views:
Transcription
1 European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe
2 PANEL MEMBERS Nathan Clumeck Chair, Brussels, Belgium Anton Pozniak, London, United Kingdom François Raffi, Nantes, France And the European AIDS Clinical Society Executive Committee Antonella d'arminio Monforte, Milan, Italy Manuel Battegay, Basel, Switzerland Nathan Clumeck, Brussels, Belgium Jose Gatell, President Barcelona, Spain Andrzej Horban, Warsaw, Poland Christine Katlama, Paris, France Jens Lundgren, Hvidovre, Denmark Santiago Moreno, Madrid, Spain Fiona Mulcahy, Secretary Dublin, Ireland Anton Pozniak, London, United Kingdom François Raffi, Nantes, France Peter Reiss, President Elect Amsterdam, The Netherlands Jürgen Rockstroh, Bonn, Germany Schlomo Staszewski, Frankfurt, Germany Mike Youle, London, United Kingdom 2/ EACS Guidelines
3 Assessment Of HIV Infected Patients at Initial and Subsequent Visits -1/2- Initial visit Complete medical history Physical examination, including height, weight, BMI, blood pressure Laboratory evaluation Confirmation of HIV antibody positive Plasma HIV RNA Resistance testing (genotype) with determination of HIV subtype CD4 absolute count + percentage (optional: CD8 and %) Complete blood count, AST, ALT, Alk phosphatase, calcium phosphate, glucose, creatinine, calculated creatinine clearance Antibody tests for toxoplasma, CMV, Hepatitis A, B and C, and syphilis Fasting blood glucose and lipids including fasting total LDL & HDL cholesterol, and triglycerides (see metabolic guidelines) Urine dipstick for protein and sugar HLA B*5701 determination (if available) Sexually Transmitted Infection screen if appropriate Women: cervical pap smear Assessment of social and psychological condition: provide support and counselling if needed Consider HAV and HBV vaccination (depending on serology results) and pneumococcal vaccination Subsequent visits (Asymptomatic patients not receiving antiretroviral therapy) At least every 6 months Complete blood count, CD4 count and %, plasma HIV RNA Every year Physical examination Evaluation of social and psychological support, smoking cessation EACS Guidelines / 3
4 Assessment Of HIV Infected Patients at Initial and Subsequent Visits -1/2- Repeat serologic testing (syphilis, CMV, toxoplasmosis, hepatitis B, hepatitis C) if previously negative AST, ALT Women: cervical pap smear If cirrhosis (regardless of cause): alphafoetoprotein + ultrasound examination Fasting lipids Treatment initiation Physical examination, including height, weight, BMI, blood pressure Plasma HIV RNA Resistance testing (genotype), if not yet obtained CD4 count and % (optional: CD8 count and %) Complete blood count, AST, ALT, bilirubin, creatinine, calculated creatinine clearance, calcium, phosphate Fasting glucose and lipids Urine dipstick for protein and sugar Other laboratory parameters may be useful according to selected first-line regimen eg protein creatinine ratio, amylase, lipase Visits on therapy Plasma HIV RNA CD4 count and % (optional: CD8 count and %) Complete blood count, creatinine, calculated creatinine clearance, AST, ALT bilirubin Other laboratory parameters according to selected regimen Fasting glucose and lipids 4/ EACS Guidelines
5 Primary HIV infection (PHI) Definition of Acute primary HIV infection High risk exposure within previous 2-8 weeks, and Clinical symptoms, and detectable HIV in the plasma (p24 Ag and/or HIV RNA > c/ml) and negative or indeterminate serologic testing (negative or weakly positive ELISA, and WB 1 band) Recommendation: confirm HIV infection by HIV antibody test (WB) performed 3-6 weeks later. Treatment: Favour clinical trial Treatment indicated if: AIDS defining events confirmed CD4 <350/mm3 at month 3 or beyond Treatment should be considered if Severe illness/prolonged symptoms (especially CNS symptoms) Treatment optional, as indication relies only on theoretical considerations. In most situations, wait till month 6 (with CD4 and plasma HIV- RNA monitoring) and follow criteria for initiation of treatment in chronic HIV infection. Some experts recommend treatment as a tool for prevention of HIV transmission. Duration of treatment: unknown but maybe should be lifelong. Maintain closer follow-up in case of treatment interruption Resistance testing: Recommended in all situations as soon as acute HIV infection is diagnosed, even if treatment not initiated In case it cannot be performed, store blood for further testing. Transmission: Recognize sexually transmitted infections (STIs), including syphilis, gonorrhoea, Chlamydia (uretritis and LGV), HPV, hepatitis B and hepatitis C. Counsel newly diagnosed patient on high risk of transmission and preventive measures (condoms) including notifying and testing partners. EACS Guidelines / 5
6 Recommendations for Initiation of Therapy in Naive HIV-Infected Patients Symptomatic Asymptomatic Resistance testing Additional remarks CDC stage B and C: treatment recommended. If OI, initiate as soon as possible* CD4 < 200: Treatment recommended, without delay. CD : treatment recommended. CD : treatment may be offered if VL>10 5 c/ml and/or CD4 decline >50-100/mm3/year or age >55 or hepatitis C co-infection CD4 > 500: treatment should be deferred, independently of Plasma HIV RNA; closer follow-up of CD4 if VL > 10 5 c/ml. Whatever CD4 and Plasma HIV RNA, treatment can be offered on an individual basis, especially if patient seeking and ready for ARV therapy Genotypic testing and subtype determination recommended, ideally at the time of HIV diagnosis, otherwise before initiation of first-line regimen If genotypic testing is not available, a ritonavirboosted PI could be preferred in the first-line regimen Before starting treatment, CD4 should be repeated and confirmed Time should be taken to prepare the patient, in order to optimize compliance and adherence * Pay particular attention to drug-drug interactions, drug toxicities, immune reconstitution syndrome and adherence, etc 6/ EACS Guidelines
7 Initial Combination Regimen for Antiretroviral-Naïve patient Select 1 drug in column A and 1 NRTI combination in column B Recommended NNRTI EFV 1 NVP 4 A B Remarks or ritonavirboosted PI fapv/r LPV/r SQV/r ABC/3TC 2-3 TDF/FTC Alternative ATV/r 5 ZDV/3TC ddi/3tc or FTC 6 ABC/3TC co-formulated TDF/FTC co-formulated fapv/r:700/100 mg bid or 1400/200 mg qd LPV/r:400/100 mg bid or 800/200 mg qd SQV/r:1000/100 mg bid or 1500/100 mg qd or 2000/100 mg qd ZDV/3TC co-formulated 1 EFV: not recommended in pregnant women or women with no reliable and consistent contraception; not active on HIV-2 and HIV-1 group O 2 Contra-indicated if HLA B*5701 positive. Even if HLA B*5701 negative, counselling on HSR risk still mandatory 3 ABC + NVP contra-indicated, unless HLA B*5701 negative 4 NVP: Use with extreme caution in women with CD4 >250 and men with CD4 >400/µL; not active on HIV-2 and HIV-1 group O 5 Approved by FDA but not yet approved by EMEA. Some physicians use ATV/r in first line regimen 6 Only if unavailable or intolerant to other recommended NRTIs EACS Guidelines / 7
8 8/ EACS Guidelines Definition General measures Virologic Failure Confirmed Plasma HIV RNA > 50 copies/ml 6 months after starting therapy (initiation or modification) in patients that remains on ART Evaluate adherence, compliance, tolerability, drug-drug interactions, drug-food interactions, psychosocial issues Perform resistance testing on failing therapy (usually reliable with plasma HIV RNA levels > copies/ml) and obtain historical resistance testing for archived mutations Consider TDM Review antiretroviral history Identify treatment options, active, potentially active drugs/combinations Management of virologic failure (VF) If Plasma HIV RNA > 50 and < copies/ml Check for adherence Check Plasma HIV RNA 1 to 2 months later Improve boosted PI's PK (if applicable) If Plasma HIV RNA confirmed > 500/1000 copies/ml, change regimen as soon as possible: what to change will depend on the resistance testing results: No Resistance mutations found: re-check for adherence, perform TDM Resistance mutations found: switch to a suppressive regimen based on drug history; multidisciplinary experts discussion advised Goal of new regimen: Plasma HIV RNA < 400 c/ml after 3 months, Plasma HIV RNA < 50 c/ml after 6 months EACS Guidelines / 9 In case of resistance mutations demonstrated General recommendations: Use 2 or preferably 3 active drugs in the new regimen (including active drugs from previously used classes) Any regimen should use at least 1 drug from a class not used previously e.g. fusion, integrase or CCR inhibitor Defer change if < 2 active drugs available, based on resistance data, except in patients with low CD4 count (<100/mm3) or with high risk of clinical deterioration for whom the goal is the preservation of immune function through partial reduction of Plasma HIV RNA (> 1 log reduction) by recycling. If limited options, consider experimental and new mechanistic drugs, favouring clinical trials (but avoid functional monotherapy) Treatment interruption is not recommended Optimisation of new regimen: Avoid NNRTI in NNRTI-experienced patients; Etravirine potentially active in selected NNRTI-resistance profiles Consider continuation of 3TC or FTC even if documented resistance mutation (M184V/I) Select other potentially active NRTI(s), on treatment history and full resistance (past and present) evaluation Select 1 active ritonavir-boosted PI. If at all possible avoid double boosted PIs Always check for drug-drug-interactions, and when necessary perform TDM of drugs of new regimen if available If many options are available, criteria of preferred choice include: simplicity of the regimen, toxicity risks evaluation, drug-drug-interactions, future salvage therapy
9 10 / EACS Guidelines Treatment of HIV Pregnant Women Pregnant women should be monitored every month and as close as possible to the predicted delivery date. Criteria for starting ART in pregnant women (see different scenario's) Same as for non pregnant Objective of treatment in pregnant women Resistance testing SCENARIO 1. Women becoming pregnant while already on ART 2. Women becoming pregnant while treatment naïve and who fulfil the criteria (CD4) for initiation of ART 3. Women becoming pregnant while treatment naïve and who do not fulfil the criteria (CD4) for initiation of ART 4. Women whose follow up starts after W28 of pregnancy Full Plasma HIV RNA suppression by third trimester and specifically at time of delivery Same as for non pregnant, i.e. before starting ART and in case of virologic failure 1. Maintain ART but switch drugs that are potentially teratogenic 2. Start ART at start of 2nd trimester is optimal 3. Start ART at start of W28 of pregnancy (at the latest 12 weeks before delivery) ; start earlier if high plasma viral load or risk of prematurity 4. Start ART immediately Antiretroviral regimen in pregnancy Same as non pregnant, Except avoid EFV ABC, NVP and TDF not to be initiated but continuation is possible if started before pregnancy Among PI/r, prefer LPV/r or SQV/r ZDV should be part of the regimen if possible Drugs contra-indicated during pregnancy IV zidovudine during labour Efavirenz, ddi + d4t, Triple NRTI combinations Benefit uncertain if Plasma HIV RNA < 50 c/ml Single dose nevirapine during labour Not recommended Caesarean section Indicated except if Plasma HIV RNA < 50 c/ml at W34-36 EACS Guidelines / 11
10 12 / EACS Guidelines Post-Exposure Prophylaxis POST-EXPOSURE PROPHYLAXIS (PEP) RECOMMENDED IF Nature of exposure Subcutaneous or intramuscular penetration with IV or IM needle, or intravascular device Status of source patient HIV + Or serostatus unknown but presence of HIV risk factors Blood Percutaneous injury with sharp instrument (lancet), IM or SC needle, suture needle Contact > 15 min of mucous membrane or non intact skin HIV + Genital secretions Anal or vaginal sex HIV + Or serostatus unknown but presence of HIV risk factors Receptive oral sex with ejaculation HIV + Intravenous drug user Exchange of syringe, needle, preparation material or any other material HIV + EACS Guidelines / 13 Rapid testing of the source patient for HCV and HIV (if HIV status unknown) recommended, If patient source HIV+ on ARV therapy, order genotyping testing if HIV- RNA > 1000 copies/µl PEP to be started ideally < 4 hours after the exposure, and no later than 48 hours Duration of PEP: 4 weeks PEP regimen: TDF/FTC (alternative: ZDV/3TC) + [LPV/r tablets 400/100 mg bid or SQV/r 1000/100 mg bid] Full sexual health screen in case of sexual exposure Follow-up: HIV serology + HBV and HCV, pregnancy test (women) within 48 hours of exposure Reevaluation of PEP indication by HIV expert within hours Assess tolerability of ARV PEP regimen Transaminases, HCV-PCR and HCV serology at month 1 if source of exposure were HCV+ (observed or suspected] Repeat HIV serology after 2 and 4 months, syphilis serology after 1 month if sexual exposure
Antiretroviral therapy for HIV infection in infants and children: Towards universal access
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
More informationCombination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
More informationOUTLINE POST EXPOSURE PROPHYLAXIS (PEP) OCCUPATIONAL RISK OF VIRAL TRANSMISSION WITH SHARP INJURY FROM INFECTED SOURCE:
Professional needle stick accidents should be dealt with within 48 hours. An ARC (Aids Reference Centre) or an emergency department must be contacted as soon as possible. OUTLINE POST EXPOSURE PROPHYLAXIS
More informationEACS 2013. Dominique Braun Universitätsspital Zürich
EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationJuly 3, 2015. III. VA policy:
Antiretroviral Postexposure Prophylaxis After Sexual, Injection- Drug Use, or Other Nonoccupational Exposure to HIV (nonoccupational post- exposure prophylaxis [npep]) VA Greater Los Angeles Healthcare
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationTheonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
More informationDidactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014
Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen
More informationChapter 3 South African guidelines and introduction to clinical cases
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
More informationUPDATE IN HIV POST-EXPOSURE PROPHYLAXIS. Weerawat Manosuthi
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS Weerawat Manosuthi Outline Case scenario of postexposure prophylaxis Risks of and how to manage postexposure prophylaxis Current PEP guideline US PHS 2013 New York
More informationPOSTEXPOSURE PROPHYLAXIS
POSTEXPOSURE PROPHYLAXIS Bloodborne viruses Hepatitis B Hepatitis C HIV Hepatitis B Risk of seroconversion HBeAg negative 2% HBeAg positive 20-40% If seroconvert most recover completely and develop immunity
More information12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV Guidelines. New Strategies.
HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV
More informationGuidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis
Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency
More informationLondon Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL
London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:
More informationTitle: Post Exposure Prophylaxis Page 1 of 8 Policy No: 1 CLN 010 Effective Date 04/15/11
Title: Post Exposure Prophylaxis Page 1 of 8 OBJECTIVE To standardize medical care following a Blood or Bodily Fluid Exposure (BBFE). SCOPE All Exposed Individuals (as defined below) who present for post-exposure
More informationRoutine HIV Monitoring
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013 VERSION 14 March 2013 Contents Acronym glossary... 2 1. Goals of the programme... 3 2. Objectives... 3 3. Specific Objectives... 3 4. Adults and
More informationHBV screening and management in HIV-infected children and adolescents
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
More informationMUSC Occupational Blood Borne Pathogen Protocol Off-Campus Procedure Packet
MUSC Occupational Blood Borne Pathogen Protocol Off-Campus Procedure Packet MUSC Medical Center has established these protocols in accordance with the OSHA Blood Borne Pathogen Standard and Center for
More informationChapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
More informationPOST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING
MARCH 2014 A Quick Guide to POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING HIV PROVIDER REFERENCE SERIES A PUBLICATION OF THE MOUNTAIN PLAINS AIDS EDUCATION AND TRAINING CENTER MountainPlains AIDS
More informationConsolidated guidelines on the use of antiretroviral drugs for treating
TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO
More informationPreventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64
Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral
More informationRegister for e-mail notification of guideline updates at http://aidsinfo.nih.gov/e-news.
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States Visit the AIDSinfo website
More informationExposure. What Healthcare Personnel Need to Know
Information from the Centers for Disease Control and Prevention National Center for Infectious Diseases Divison of Healthcare Quality Promotion and Division of Viral Hepatitis For additional brochures
More informationUK prevalence in pregnancy and risk of transmission
UK prevalence in pregnancy and risk of transmission In 2009 HIV prevalence in the UK among women giving birth was 2.2 per 1000 The majority of these women are from sub-saharan Africa with a prevalence
More informationPost-Exposure Prophylaxis
Post-Exposure Prophylaxis Health Worker Safety Training Module 4: Post-Exposure Prophylaxis Health Worker Safety Training Module 2 Topics What is PEP? Infectious body fluids Types of exposures requiring
More informationClinical rationale for viral load testing
Clinical rationale for viral load testing Francois Venter Wits Reproductive Health & HIV Institute Caveats I m a believer in VLs My talk looks at resource poor environments Why do we need a rationale???
More informationFrequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013
Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013 On July 16, 2012, the Food and Drug Administration (FDA) approved
More informationPEP Step 2: Report and Document
RISK The risk of exposure to blood and bloodborne pathogens is slightly greater for health care personnel (HCP) than for people who do not work around blood. An exposure to infected blood, tissue, or other
More informationPaediatric HIV treatment update
Paediatric HIV treatment update James Nuttall Red Cross War Memorial Children s Hospital & University of Cape Town ART Resistance & New Treatment Options 6 th FIDSSA Conference, 5-7 November 2015 ART Eligibility
More informationThe Basics of Drug Resistance:
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
More informationOutpatient/Ambulatory Health Services
Outpatient/Ambulatory Health Services Service Definition Outpatient/ambulatory medical care includes the provision of professional diagnostic and therapeutic services rendered by a physician, physician
More informationFrequently Asked Questions
Frequently Asked Questions Testing for Gonorrhea Q1: What test should be completed for accurately diagnosing gonorrhea? A1: Testing is done with either a culture or a NAAT (nucleic acid amplification test).
More informationSwitch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort
Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort Gaetana Sterrantino Azienda Ospedaliero-Universitaria Careggi Infectious diseases, Florence, Italy Background
More informationBloodborne Pathogens (HIV, HBV, and HCV) Exposure Management
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
More informationProtease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa T. Sonia Boender; Raph L. Hamers; Pascale Ondoa; Maureen Wellington; Cleophas Chimbetete; Margaret Siwale; Eman E F
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) Guidance from the Michigan Department of Health and Human Services Division of Health, Wellness & Disease Control Revised June 2015 The Michigan Department
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationTreatment Information Service 1 800 HIV 0440 HIV/AIDS. HIV and Its Treatment What You Should Know. 2nd edition
HIV/AIDS Treatment Information Service 1 800 HIV 0440 HIV and Its Treatment What You Should Know 2nd edition HIV/AIDS TREATMENT INFORMATION SERVICE 2nd Edition HIV and Its Treatment: What You Should Know
More informationCore Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.
Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* ABOUT THIS ACTIVITY Time: 60 minutes Objectives: By the end of this session, participants will be able to: Reviewed their knowledge of HIV/AIDS
More informationGARPR Online Reporting Tool
GARPR Online Reporting Tool 0 Narrative Report and Cover Sheet 1) Which institutions/entities were responsible for filling out the indicator forms? a) NAC or equivalent Yes b) NAP Yes c) Others Yes If
More informationFrequently Asked Questions
Guidelines for Testing and Treatment of Gonorrhea in Ontario, 2013 Frequently Asked Questions Table of Contents Background... 1 Treatment Recommendations... 2 Treatment of Contacts... 4 Administration
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationPost-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV. National Guidelines
Post-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV National Guidelines National guidelines for post-exposure prophylaxis after non-occupational and occupational exposure
More informationHIV Drug resistanceimplications
HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:
More informationNational Antiretroviral Treatment Guidelines
National Antiretroviral Treatment Guidelines Copyright 2004 Department of Health Published by Jacana Printed by Minuteman Press ISBN: 1-919931-69-4 National Department of Health South Africa 2004 This
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHIV. Head - Paediatric HIV Treatment Programmes. Right to Care. Dr Leon Levin
HIV Dr Leon Levin Head - Paediatric HIV Treatment Programmes Right to Care Disclaimer This talk represents my personal experience in managing teenagers with HIV over the last 14 years. It does not purport
More informationHIV/AIDS: Controversies 2008-10
HIV/AIDS: Controversies 2008-10 1. Prevention 2. Treatment Josep M Gatell Hospital Clinic. Barcelona. gatell0@attglobal.net AIDS: year 2008-10 AIDS is a STD and a world wide epidemy (sub-saharan Africa,
More informationManagement of HIV and TB Co-infection in South Africa
Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy
More informationPrevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis. John Ferguson, UPNG 2012
Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis John Ferguson, UPNG 2012 Outline Epidemiology Making the diagnosis / contact tracing Antiretroviral
More informationHIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016
HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016 Daily emtricitabine/tenofovir (Truvada ) is safe and effective for reducing the risk of HIV acquisition in sexually
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More information4/15/2010. Vermont Department of Health STD/HIV Program Vermont Department of Health STD/HIV Program. Vermont Department of Health STD/HIV Program
First Let s Look at Some Numbers HIV Postexposure Prophylaxis for Occupational and Non- occupational Exposure National Vermont VtSHP Annual Meeting 4/10/10 Deborah Kutzko FNP "Financial support for this
More informationHPTN 073: Black MSM Open-Label PrEP Demonstration Project
HPTN 073: Black MSM Open-Label PrEP Demonstration Project Overview HIV Epidemiology in the U.S. Overview of PrEP Overview of HPTN HPTN 061 HPTN 073 ARV Drug Resistance Conclusions Questions and Answers
More informationTHIS IS AN OFFICIAL NH DHHS HEALTH ALERT
THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network Health.Alert@nh.gov August 13, 2015 1400 EDT (2:00 PM EDT) NH-HAN 20150813 Updated Centers for Disease Control (CDC)
More informationHIV Post Exposure Prophylaxis Update
HIV Post Exposure Prophylaxis Update Mary Goodspeed, RN, BS 716-898-4713 Coordinator, HIV Clinical Education Initiative Erie County Medical Center, Buffalo, NY PEP Hotline 1-888-448-4911 www.aidscenterecmc.org
More informationBritish HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
r 2006 British HIV Association HIV Medicine (2006), 7, 487 503 British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) B Gazzard on behalf
More informationDOI: 10.1111/hiv.12217 on behalf of British HIV Association. HIV Medicine (2015) ORIGINAL RESEARCH
DOI: 10.1111/hiv.12217. ORIGINAL RESEARCH Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationThis document was made possible through the financial support of the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM).
This document was made possible through the financial support of the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM). The contents are the responsibility of the Ministry of Health and do not
More informationFAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.
HIV & AIDS What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease. What does HIV stand for? Human Immunodeficiency Virus Where did HIV
More informationCOMMUNICABLE DISEASE
Public Health Activities & Services Inventory Technical Notes COMMUNICABLE DISEASE CLINICAL SERVICES, SURVEILLANCE AND CONTROL In 2014, decision was made to adopt number of national public health activities
More informationGuidelines for Managing Exposures to Blood Borne Pathogens
Guidelines for Managing Exposures to Blood Borne Pathogens Revised May 2010 Table of Contents Introduction 1 Exposure to Blood/Body Fluids 2 A. Initial Management Guidelines I. General Measures 2 II. Evaluate
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationPREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION
PREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION Health Plan of Nevada and Sierra Health and Life suggest that health plan members get certain screening tests, exams and shots to stay healthy. This document
More informationARV treatment Update 2012. Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen
ARV treatment Update 2012 Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen Three big conferences in 2012 http://retroconference.org/2012/ http://www.aids2012.org/ http://www.hiv11.com/ Current
More informationThe Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and
The Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to- Child Transmission of HIV (PMTCT), Children, Adolescents and Adults. 2015 (Amended Version) The Western Cape Consolidated
More informationBody Fluid Exposure:
Focus on CME at the University of Manitoba Focus on CME at the University of Manitoba Body Fluid Exposure: What To Do? John Sokal, MD, CFPC Presented at Bug Day 2003, Health Sciences Centre, Winnipeg (October
More informationHIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline
HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline Background... 2 Screening... 2 Recommendations... 2 Ordering and consent... 2 Indications for Periodic HIV Screening...
More informationGeneric antiretrovirals in Europe: a blessing or a curse?
Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade
More informationMANAGEMENT OF INFANTS BORN TO HIV POSITIVE MOTHERS
MANAGEMENT OF INFANTS BORN TO HIV POSITIVE MOTHERS Introduction Perinatal management of infants born to HIV-infected mothers requires a coordinated multidisciplinary team approach. The consultant leads
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationCalifornia Guidelines for STD Screening and Treatment in Pregnancy
California Guidelines for STD Screening and Treatment in Pregnancy These guidelines were developed by the California Department of Public Health (CDPH) Sexually Transmitted Diseases (STD) Control Branch
More informationAntiretroviral Drugs in the Treatment and Prevention of HIV Infection
Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Noga Shalev, MD Uses of Antiretroviral Agents Treatment of chronic HIV infection Prevention of mother-to-child transmission [PMTCT]
More informationOCCUPATIONAL HEALTH, DISABILITY AND LEAVE SECTOR MEASURES TO MINIMIZE EXPOSURE TO BLOODBORNE PATHOGENS AND POST-EXPOSURE PROPHYLAXIS POLICY
UNIVERSITY OF OTTAWA OCCUPATIONAL HEALTH, DISABILITY AND LEAVE SECTOR MEASURES TO MINIMIZE EXPOSURE TO BLOODBORNE PATHOGENS AND POST-EXPOSURE PROPHYLAXIS POLICY Prepared by the Occupational Health, Disability
More informationWilliam Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016
William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15
More informationAppendix 3 Exposure Incident Report Form
Appendix 3 Exposure Incident Report Form January, 2015 Page 1 of 6 Please see the following pages for the Exposure Incident Report Form. Guidelines for the Management of Exposure to Blood and Body Fluids
More informationGuidelines for Viral Hepatitis CTR Services
Guidelines for Viral Hepatitis CTR Services During the 2007 North Dakota Legislative Assembly, legislation that called for the creation of a viral hepatitis program was introduced and approved. The North
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationSOGC recommendation on ZIKA virus exposure for clinicians caring for pregnant women and those who intend to get pregnant
SOGC recommendation on ZIKA virus exposure for clinicians caring for pregnant women and those who intend to get pregnant Foreword The rapid emergence of Zika virus as a potential causative agent for fetal
More informationThe Role of the Primary Care Clinician in HIV Care
The Role of the Primary Care Clinician in HIV Care Jeffrey Kwong, DNP, ANP-BC, AAHIVS, ACRN, FAANP Columbia University School of Nursing New York, NY New York Nurse Practitioner Association Annual Meeting
More informationBRITISH COLUMBIA GUIDELINES FOR THE CARE OF HIV POSITIVE PREGNANT WOMEN AND INTERVENTIONS TO REDUCE PERINATAL TRANSMISSION
BRITISH COLUMBIA GUIDELINES FOR THE CARE OF HIV POSITIVE PREGNANT WOMEN AND INTERVENTIONS TO REDUCE PERINATAL TRANSMISSION July 23, 2013 Page 1 of 107 TABLE OF CONTENTS: Summary of recommendations Introduction
More informationPreventive Services Explained
Preventive Services Explained Medicare covers many preventive care services without charge. Most of these services have been recommended by the U.S. Preventive Services Task Force. However, which beneficiaries
More informationOffering HIV Post-Exposure Prophylaxis (PEP) Following Non-Occupational Exposures
Offering HIV Post-Exposure Prophylaxis (PEP) Following Non-Occupational Exposures Recommendations for Health Care Providers in the State of California Arnold Schwarzenegger Governor State of California
More informationFirst Visit Basics MPAETC 2009 1. A Guide for Primary Care Providers
First Visit Basics 1 A Guide for Primary Care Providers 2 First Visit Basics: Initiating Care for the HIV-Infected Patient Editor: Jeffrey Kwong, MS, MPH, ANP, ACRN Clinical Education Coordinator, Mountain
More informationPaediatric HIV Drug Resistance in African Settings
Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia Background: ART for children in sub- Saharan Africa 2.3 million children with HIV
More informationManaging Bloodborne Pathogens Exposures
Managing Bloodborne Pathogens Exposures House Staff Orientation 2015 Phillip F. Bressoud, MD, FACP Associate Professor of Medicine and Executive Director Campus Health Services University of Louisville
More informationAntiretroviral Treatment
Antiretroviral Treatment Michael A. Tolle, MD, MPH Heidi Schwarzwald, MD, MPH Nancy R. Calles, MSN, PNP, ACRN, MPH Objectives 1. Discuss the goals of treatment for human immunodeficiency virus (HIV) infection.
More informationPreventive Care Recommendations THE BASIC FACTS
Preventive Care Recommendations THE BASIC FACTS MULTIPLE SCLEROSIS Carlos Healey, diagnosed in 2001 The Three Most Common Eye Disorders in Multiple Sclerosis Blood Pressure & Pulse Height & Weight Complete
More informationGUIDELINES. Version 8.0 October 2015. English
GUIDELINES Version 8.0 October 2015 English Table of Contents Panel Members 2 Governing Board Members 2 Abbreviations 3 Green text = online only at http://www.eacsociety.g and in the EACS Guidelines App.
More informationTreatment 2.0 as a catalyst for Tasp through Drug / Treatment Optimization
Treatment 2.0 as a catalyst for Tasp through Drug / Treatment Optimization STEFANO VELLA MD ISTITUTO SUPERIORE DI SANITÀ ROME - ITALY DDF 6 WAFAA EL SADR, CROI 2012 The problem is in how to efficiently
More information